{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T04:11:26Z","timestamp":1748232686777},"reference-count":68,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.cpet.2024.05.004","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T22:19:04Z","timestamp":1720131544000},"page":"525-534","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Symptomatic Myeloma"],"prefix":"10.1016","volume":"19","author":[{"given":"Alice","family":"Rossi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arrigo","family":"Cattabriga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Bezzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpet.2024.05.004_bib1","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.cpet.2024.05.004_bib2","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cpet.2024.05.004_bib3","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cpet.2024.05.004_bib4","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s11604-018-0738-z","article-title":"Diagnostic performance of 18F-FDG-PET\/CT and whole-body MRI before and early after treatment of multiple myeloma: a prospective comparative study","volume":"36","author":"Basha","year":"2018","journal-title":"Jpn J Radiol"},{"key":"10.1016\/j.cpet.2024.05.004_bib5","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.3332\/ecancer.2021.1164","article-title":"Whole-body magnetic resonance imaging: technique, guidelines and key applications","volume":"15","author":"Summers","year":"2021","journal-title":"Ecancermedicalscience"},{"issue":"8","key":"10.1016\/j.cpet.2024.05.004_bib6","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1007\/s11547-023-01665-y","article-title":"Patient centered radiology: investigating 3 Tesla whole body MRI acceptance in cancer patients","volume":"128","author":"Rossi","year":"2023","journal-title":"Radiol Med"},{"issue":"1081","key":"10.1016\/j.cpet.2024.05.004_bib7","doi-asserted-by":"crossref","first-page":"20170577","DOI":"10.1259\/bjr.20170577","article-title":"UK quantitative WB-DWI technical workgroup: consensus meeting recommendations on optimisation, quality control, processing and analysis of quantitative whole-body diffusion-weighted imaging for cancer","volume":"91","author":"Barnes","year":"2018","journal-title":"Br J Radiol"},{"key":"10.1016\/j.cpet.2024.05.004_bib8","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of 18F-FDG-PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cpet.2024.05.004_bib9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2967\/jnumed.107.045641","article-title":"18F-FDG PET\/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma","volume":"49","author":"Fonti","year":"2008","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2024.05.004_bib10","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1016\/j.ejrad.2012.06.028","article-title":"Contrast enhanced MRI and (1)(8)F-FDG PET-CT in the assessment of multiple myeloma: a comparison of results in different phases of the disease","volume":"81","author":"Spinnato","year":"2012","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.cpet.2024.05.004_bib11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3324\/haematol.10554","article-title":"A\u00a0prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma","volume":"92","author":"Zamagni","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.cpet.2024.05.004_bib12","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1182\/blood.V126.23.395.395","article-title":"Prospective evaluation of MRI and PET-CT at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 Trial","volume":"126","author":"Moreau","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.cpet.2024.05.004_bib13","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1148\/radiol.2522081756","article-title":"Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinalMR imaging","volume":"252","author":"Bauerle","year":"2009","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.cpet.2024.05.004_bib14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1148\/radiol.2019181949","article-title":"Guidelines for acquisition, interpretation, and reporcing of whole-body MRI in myeloma: myeloma response assessment and diagnosis system (MY-RADS)","volume":"291","author":"Messiou","year":"2019","journal-title":"Radiology"},{"issue":"1152","key":"10.1016\/j.cpet.2024.05.004_bib15","doi-asserted-by":"crossref","first-page":"20230240","DOI":"10.1259\/bjr.20230240","article-title":"Relative fat fraction of malignant bone lesions from breast cancer, prostate cancer and myeloma are significantly lower than normal bone marrow and shows excellent interobserver agreement","volume":"96","author":"Castagnoli","year":"2023","journal-title":"Br J Radiol"},{"issue":"5","key":"10.1016\/j.cpet.2024.05.004_bib16","doi-asserted-by":"crossref","first-page":"e210048","DOI":"10.1148\/rycan.2021210048","article-title":"Prospective evaluation of whole-body MRI versus FDG PET\/CT for lesion detection in participants with myeloma","volume":"3","author":"Messiou","year":"2021","journal-title":"Radiol Imaging Cancer"},{"key":"10.1016\/j.cpet.2024.05.004_bib17","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1007\/s00277-020-04265-2","article-title":"Prospective comparison of 18-FDG PET\/CT and whole-body diffusionweighted MRI in the assessment of multiple myeloma","volume":"99","author":"Mesguich","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.cpet.2024.05.004_bib18","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1007\/s00259-020-05182-2","article-title":"Comparison of the diagnostic performance and impact on management of 18F-FDG PET\/CT and whole-body MRI in multiple myeloma","volume":"48","author":"Westerland","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.cpet.2024.05.004_bib19","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1053\/j.semnuclmed.2022.10.008","article-title":"Clinical value of FDG-PET\/CT in multiple myeloma: an update","volume":"53","author":"Bezzi","year":"2023","journal-title":"Semin Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2024.05.004_bib20","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","article-title":"Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma","volume":"130","author":"Rasche","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cpet.2024.05.004_bib21","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00259-019-04312-9","article-title":"Low hexokinase-2 expression-associated false-negative (18)F-FDG-PET\/CT as a potential prognostic predictor in patients with multiple myeloma","volume":"46","author":"Abe","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2024.05.004_bib22","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.2967\/jnumed.121.262884","article-title":"Molecular signature of 18F-FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genome-wide transcriptome analysis from the CASSIOPET study","volume":"63","author":"Alberge","year":"2022","journal-title":"J\u00a0Nucl Med"},{"issue":"19","key":"10.1016\/j.cpet.2024.05.004_bib23","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1158\/1078-0432.CCR-15-0396","article-title":"PET\/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma","volume":"21","author":"Zamagni","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cpet.2024.05.004_bib24","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00330-019-06469-1","article-title":"MRI versus (18)F-FDG-PET\/CT for detecting bone marrow involvement in multiple myeloma: diagnostic performance and clinical relevance","volume":"30","author":"Lecouvet","year":"2020","journal-title":"Eur Radiol"},{"issue":"9","key":"10.1016\/j.cpet.2024.05.004_bib25","doi-asserted-by":"crossref","first-page":"6438","DOI":"10.1007\/s00330-023-09593-1","article-title":"Hybrid simultaneous whole-body 2-[18F]FDG-PET\/MRI imaging in newly diagnosed multiple myeloma: first diagnostic performance and clinical added value results","volume":"33","author":"Jamet","year":"2023","journal-title":"Eur Radiol"},{"key":"10.1016\/j.cpet.2024.05.004_bib26","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjh.17338","article-title":"Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations","volume":"194","author":"Rosinol","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.cpet.2024.05.004_bib27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood-2018-04-842880","article-title":"The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma","volume":"132","author":"Rasche","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cpet.2024.05.004_bib28","doi-asserted-by":"crossref","first-page":"514","DOI":"10.2214\/AJR.18.20989","article-title":"Comparison of whole-body DWI and 18F-FDG PET\/CT for detecting intramedullary and extramedullary lesions in multiple myeloma","volume":"213","author":"Chen","year":"2019","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"10.1016\/j.cpet.2024.05.004_bib29","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/RLU.0000000000003512","article-title":"Agreement between 18F-FDG PET\/CT and whole-body magnetic resonance compared with skeletal survey for initial staging and response at end-of-treatment evaluation of patients with multiple myeloma","volume":"46","author":"G\u00f3mez Le\u00f3n","year":"2021","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.cpet.2024.05.004_bib30","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s00330-020-07177-x","article-title":"Prognostic value of 18F-fluorodeoxyglucose positron emission tomography\/computed tomography in newly diagnosed multiple myeloma: a systematic review and meta-analysis","volume":"31","author":"Han","year":"2021","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1016\/j.cpet.2024.05.004_bib31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10238-023-01279-8","article-title":"Prognostic value of 18F-fluorodeoxyglucose positron emission tomography\/computed tomography at diagnosis in untreated multiple myeloma patients: a systematic review and meta-analysis","volume":"23","author":"Li","year":"2023","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.cpet.2024.05.004_bib32","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1038\/s41467-022-32145-y","article-title":"The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states","volume":"13","author":"Rasche","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.cpet.2024.05.004_bib33","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1200\/JCO.2006.08.5803","article-title":"Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications","volume":"25","author":"Walker","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpet.2024.05.004_bib34","doi-asserted-by":"crossref","first-page":"818","DOI":"10.3324\/haematol.2015.124115","article-title":"A\u00a0magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma","volume":"100","author":"Mai","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.cpet.2024.05.004_bib35","doi-asserted-by":"crossref","first-page":"780078","DOI":"10.3389\/fonc.2022.780078","article-title":"The apparent diffusion coefficient of diffusion-weighted whole-body magnetic resonance imaging affects the survival of multiple myeloma independently","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.cpet.2024.05.004_bib36","doi-asserted-by":"crossref","first-page":"e230667","DOI":"10.1148\/radiol.230667","article-title":"Development of a semiquantitative whole-body MRI scoring system for multiple myeloma","volume":"308","author":"Kim","year":"2023","journal-title":"Radiology"},{"key":"10.1016\/j.cpet.2024.05.004_bib37","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.mri.2020.10.005","article-title":"Characterising spatial heterogeneity of multiple myeloma in high resolution by whole body magnetic resonance imaging: towards macro-phenotype driven patient management","volume":"75","author":"Latifoltojar","year":"2021","journal-title":"Magn Reson Imaging"},{"key":"10.1016\/j.cpet.2024.05.004_bib38","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1182\/bloodadvances.2022007052","article-title":"Utility of PET\/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma","volume":"6","author":"Charalampous","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.cpet.2024.05.004_bib39","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3324\/haematol.2017.177139","article-title":"Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma","volume":"103","author":"Davies","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.cpet.2024.05.004_bib40","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.3390\/cancers12041030","article-title":"PET-FDG: impetus","volume":"12","author":"Nanni","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cpet.2024.05.004_bib41","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13550-021-00846-y","article-title":"The prognostic significance of [18F] FDG-PET\/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs)","volume":"11","author":"Sachpekidis","year":"2021","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.cpet.2024.05.004_bib42","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.20.00386","article-title":"Standardization of 18F-FDG-PET\/CT according to deauville criteria for metabolic complete response definition in newly diagnosed multiple myeloma","volume":"39","author":"Zamagni","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpet.2024.05.004_bib43","doi-asserted-by":"crossref","first-page":"102017","DOI":"10.1016\/j.eclinm.2023.102017","article-title":"Impact of minimal residual disease standardised assessment by FDG-PET\/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial","volume":"60","author":"Zamagni","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.cpet.2024.05.004_bib44","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s00330-012-2600-5","article-title":"Comparative diagnostic performance of (1)(8)F-FDG PET\/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation","volume":"23","author":"Derlin","year":"2013","journal-title":"Eur Radiol"},{"key":"10.1016\/j.cpet.2024.05.004_bib45","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","volume":"35","author":"Moreau","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2024.05.004_bib46","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1148\/radiol.211388","article-title":"Comparison of MRI features of fat fraction and ADC for early treatment response assessment in participants with multiple myeloma","volume":"304","author":"Koutoulidis","year":"2022","journal-title":"Radiology"},{"key":"10.1016\/j.cpet.2024.05.004_bib47","doi-asserted-by":"crossref","first-page":"808627","DOI":"10.3389\/fnume.2021.808627","article-title":"18F-FDG PET\/CT and MRI in the management of multiple myeloma: a comparative review","volume":"1","author":"Mesguich","year":"2022","journal-title":"Front. Nucl. Med"},{"issue":"4","key":"10.1016\/j.cpet.2024.05.004_bib48","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1148\/rg.2019180096","article-title":"Whole-body imaging of multiple myeloma: diagnostic criteria","volume":"39","author":"Ormond Filho","year":"2019","journal-title":"Radiographics"},{"key":"10.1016\/j.cpet.2024.05.004_bib49","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.acra.2017.12.008","article-title":"Discriminating depth of response to therapy in multiple myeloma using whole-body diffusion-weighted MRI with apparent diffusion coefficient","volume":"25","author":"Wu","year":"2018","journal-title":"Acad Radiol"},{"key":"10.1016\/j.cpet.2024.05.004_bib50","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1007\/s00330-021-08311-z","article-title":"Application of diffusion-weighted whole-body MRI for response monitoring in multiple myeloma after chemotherapy: a systematic review and meta-analysis","volume":"32","author":"Wang","year":"2022","journal-title":"Eur Radiol"},{"key":"10.1016\/j.cpet.2024.05.004_bib51","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00256-022-04119-0","article-title":"Diffusion- weighted imaging (DWI) in diagnosis, staging, and treatment response assessment of multiple myeloma: a systematic review and meta-analysis","volume":"52","author":"Torkian","year":"2023","journal-title":"Skeletal Radiol"},{"issue":"1120","key":"10.1016\/j.cpet.2024.05.004_bib52","doi-asserted-by":"crossref","first-page":"20200682","DOI":"10.1259\/bjr.20200682","article-title":"Repeatability and reproducibility of apparent diffusion coefficient and fat fraction measurement of focal myeloma lesions on whole body magnetic resonance imaging","volume":"94","author":"Barwick","year":"2021","journal-title":"Br J Radiol"},{"issue":"7","key":"10.1016\/j.cpet.2024.05.004_bib53","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1007\/s00330-020-07522-0","article-title":"Repeatability and reproducibility of ADC measurements: a prospective multicenter whole-body-MRI study","volume":"31","author":"Michoux","year":"2021","journal-title":"Eur Radiol"},{"issue":"17","key":"10.1016\/j.cpet.2024.05.004_bib54","doi-asserted-by":"crossref","first-page":"5859","DOI":"10.1002\/cam4.4136","article-title":"Predictive role of diffusion-weighted whole-body MRI (DW-MRI) imaging response according to MY-RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry","volume":"10","author":"Belotti","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.cpet.2024.05.004_bib55","doi-asserted-by":"crossref","first-page":"110493","DOI":"10.1016\/j.ejrad.2022.110493","article-title":"Multi-parametric whole-body MRI evaluation discerns vital from non-vital multiple myeloma lesions as validated by 18F-FDG and 11C-methionine PET\/CT","volume":"155","author":"Heidemeier","year":"2022","journal-title":"Eur J Radiol"},{"issue":"4","key":"10.1016\/j.cpet.2024.05.004_bib56","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2214\/AJR.21.26381","article-title":"Comparative performance of whole-body MRI and FDG PET\/CT in evaluation of multiple myeloma treatment response: systematic review and meta-analysis","volume":"218","author":"Rama","year":"2022","journal-title":"AJR Am J Roentgenol"},{"issue":"7","key":"10.1016\/j.cpet.2024.05.004_bib57","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41375-018-0329-0","article-title":"Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma","volume":"33","author":"Rasche","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.cpet.2024.05.004_bib58","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.3390\/cancers13081938","article-title":"Prospective comparison of 18-FDG PET\/CT and whole-body MRI with diffusion-weighted imaging in the evaluation of treatment response of multiple myeloma patients eligible for autologous stem cell transplant","volume":"13","author":"Mesguich","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cpet.2024.05.004_bib59","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.3390\/cancers13174332","article-title":"Minimal residual disease in multiple myeloma: something old, something new","volume":"13","author":"Bravo-Perez","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cpet.2024.05.004_bib60","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ajh.25507","article-title":"Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma","volume":"94","author":"Alonso","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cpet.2024.05.004_bib61","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.3390\/ijms21155406","article-title":"Functional imaging for therapeutic assessment and minimal residual disease detection in multiple myeloma","volume":"21","author":"Jamet","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.cpet.2024.05.004_bib62","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-023-00794-x","article-title":"Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients","volume":"13","author":"Fonseca","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.cpet.2024.05.004_bib63","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41375-020-01012-4","article-title":"International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials","volume":"35","author":"Costa","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.cpet.2024.05.004_bib64","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/bjh.18249","article-title":"Minimal residual disease and imaging-guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma","volume":"198","author":"Bockle","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cpet.2024.05.004_bib65","doi-asserted-by":"crossref","first-page":"801792","DOI":"10.3389\/fnume.2022.801792","article-title":"Molecular imaging in multiple myeloma\u2014novel PET radiotracers improve patient management and guide therapy","volume":"2","author":"von Hinten","year":"2022","journal-title":"Front. Nucl. Med"},{"issue":"5","key":"10.1016\/j.cpet.2024.05.004_bib66","first-page":"195","article-title":"Marriage of radiotracers and total-body PET\/CT rapid imaging system: current status and clinical advances","volume":"13","author":"Wu","year":"2023","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2024.05.004_bib67","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00259-016-3502-6","article-title":"Treatment response evaluation with 18F-FDG PET\/CT and 18F-NaF PET\/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation","volume":"44","author":"Sachpekidis","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2024.05.004_bib68","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1007\/s00330-021-08388-6","article-title":"Optimization of whole-body 2- [18F]FDG-PET\/MRI imaging protocol for the initial staging of patients with myeloma","volume":"32","author":"Burns","year":"2022","journal-title":"Eur Radiol"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859824000506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859824000506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T22:04:24Z","timestamp":1724882664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859824000506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1556859824000506"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2024.05.004","relation":{},"ISSN":["1556-8598"],"issn-type":[{"type":"print","value":"1556-8598"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Symptomatic Myeloma","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2024.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}